Appili Therapeutics Inc. was specifically founded to advance the global fight against infectious disease. Our team follows a rigorous process to identify and evaluate drug development opportunities, and to ensure that they align optimally with unmet patient and market needs.
Without being bound to an indication or platform technology, we have the flexibility to deploy our ‘balanced risk’ approach to building our pipeline: a deliberate mix of close-to-market/revenue assets that provide near-term value and cash flow, coupled with cutting-edge, transformational programs that could change how we treat infectious disease.
Near to market/revenue or
Transformational programs to
tackle the most serious threats